Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $(0.03) by 1100 percent. This is a 850 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $299.000 thousand which missed the analyst consensus estimate of $1.388 million by 78.46 percent. This is a 43.48 percent decrease over sales of $529.000 thousand the same period last year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.